Latest Momenta Pharmaceuticals (MNTA) Headlines
Post# of 59
Posted On: 03/12/2014 11:52:12 PM
Latest Momenta Pharmaceuticals (MNTA) Headlines
Teva upgraded on drug launch
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The generic-drug maker was upgraded to outperform by Leerink Partners on the rise of its multiple-sclerosis drug. According to the analyst's survey, 40% of users are estimated to switch to Teva Pharmaceutical's (TEVA) new 40-milligram, thrice-weekly...
Teva Upgraded On Strong Launch Of Next-Gen Copaxone
at Investor's Business Daily - Thu Mar 06, 11:03AM CST
Leerink Partners upgraded Teva Pharmaceutical Industries (TEVA) to outperform Thursday, sending the stock up to a three-year high on the stock market today. Analyst Jason Gerberry wrote that his survey of the multiple-sclerosis market showed strong...
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Mon Feb 24, 3:05PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Cowen and Company 34th Annual Health Care Conference will be webcast on Monday, March 3 at 3:30 p.m. ET.
Momenta Reports Wider Loss, Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:39AM CST
Momenta Pharma reported 4Q13 net loss per share of 59 cents, wider than the Zacks Consensus Estimate of a loss of 45 cents. The year-ago loss was 35 cents.
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Mon Feb 10, 7:01AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2013.
Momenta Pharmaceuticals to Webcast Presentation at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 7:30AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 Leerink Global Healthcare Conference will be webcast on Wednesday, February 12 at 3:55 p.m. ET.
Teva: Attempting to Dodge Wrenches
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 03, 7:00AM CST
Drug makers have a love hate relationship with the FDA. The U.S. regulatory watchdog is responsible not only for approving their drugs, but also for approving generic competitors. This year, the FDA could be both Teva's best friend and worst...
Shares of MNTA Up 17.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 30, 11:10AM CST
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on October 16th, 2013 at $15.92. In approximately 4 months, Momenta Pharmaceuticals has returned 17.53% as of today's recent price of $18.71.
Momenta Pharmaceuticals Shares Up 20.9% Since SmarTrend's Buy Recommendation (MNTA)
Comtex SmarTrend(R) - Thu Jan 23, 9:46AM CST
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on October 16th, 2013 at $15.92. In approximately 3 months, Momenta Pharmaceuticals has returned 20.85% as of today's recent price of $19.24.
Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee
PR Newswire - Thu Jan 23, 7:00AM CST
Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions.
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Jan 21, 3:05PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2013 before the U.S. financial markets open on Monday, February 10, 2014.
22.5% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Thu Jan 16, 9:12AM CST
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on October 16th, 2013 at $15.92. In approximately 3 months, Momenta Pharmaceuticals has returned 22.49% as of today's recent price of $19.50.
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
Commercialization Agreements, Acquisition Updates, Conference Calls Schedules, Stock Price Updates and Clinical Study Data - Research Report on Biogen Idec, Covidien, Vertex, Endo, and Momenta Pharma
PR Newswire - Tue Dec 31, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Covidien plc (NYSE: COV), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Endo Health Solutions Inc. (NASDAQ: ENDP), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
9 Top Stocks to Buy in 2014
Motley Fool Staff - Motley Fool - Sat Dec 21, 7:20AM CST
As a new year approaches, we decided to ask some of our top analysts for their favorite stock idea for 2014. Here are nine companies that look compelling right now. Jim Gillies : It's hard to find a positive word about IBM (NYSE: IBM)...
3 Quick Conclusions on a Dropped Biosimilar at Momenta Pharmaceuticals
Maxx Chatsko, The Motley Fool - Motley Fool - Fri Dec 20, 3:42PM CST
On December 19, Baxter International notified Momenta Pharmaceuticals that it was no longer interested in developing M511, a monoclonal antibody biosimilar for cancer, under a collaboration formed two years ago. The partnership sought to...
Strategic Acquisitions, Commercial Collaborations, and New Appointments - Research Report on Solta Medical, Opko Health, NuPathe, AcelRx Pharmaceuticals, and Momenta Pharmaceuticals
PR Newswire - Thu Dec 19, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Solta Medical, Inc. (NASDAQ: SLTM), Opko Health, Inc. (NYSE: OPK), NuPathe, Inc. (NASDAQ: PATH), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AnaptysBio Announces Antibody Development Agreement With Momenta
PR Newswire - Tue Dec 17, 7:00AM CST
AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the initiation of an antibody development program with Momenta Pharmaceuticals, Inc. focused on the development of novel antibodies against a therapeutically relevant target.
Teva upgraded on drug launch
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The generic-drug maker was upgraded to outperform by Leerink Partners on the rise of its multiple-sclerosis drug. According to the analyst's survey, 40% of users are estimated to switch to Teva Pharmaceutical's (TEVA) new 40-milligram, thrice-weekly...
Teva Upgraded On Strong Launch Of Next-Gen Copaxone
at Investor's Business Daily - Thu Mar 06, 11:03AM CST
Leerink Partners upgraded Teva Pharmaceutical Industries (TEVA) to outperform Thursday, sending the stock up to a three-year high on the stock market today. Analyst Jason Gerberry wrote that his survey of the multiple-sclerosis market showed strong...
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Mon Feb 24, 3:05PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Cowen and Company 34th Annual Health Care Conference will be webcast on Monday, March 3 at 3:30 p.m. ET.
Momenta Reports Wider Loss, Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:39AM CST
Momenta Pharma reported 4Q13 net loss per share of 59 cents, wider than the Zacks Consensus Estimate of a loss of 45 cents. The year-ago loss was 35 cents.
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Mon Feb 10, 7:01AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2013.
Momenta Pharmaceuticals to Webcast Presentation at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 7:30AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 Leerink Global Healthcare Conference will be webcast on Wednesday, February 12 at 3:55 p.m. ET.
Teva: Attempting to Dodge Wrenches
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 03, 7:00AM CST
Drug makers have a love hate relationship with the FDA. The U.S. regulatory watchdog is responsible not only for approving their drugs, but also for approving generic competitors. This year, the FDA could be both Teva's best friend and worst...
Shares of MNTA Up 17.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 30, 11:10AM CST
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on October 16th, 2013 at $15.92. In approximately 4 months, Momenta Pharmaceuticals has returned 17.53% as of today's recent price of $18.71.
Momenta Pharmaceuticals Shares Up 20.9% Since SmarTrend's Buy Recommendation (MNTA)
Comtex SmarTrend(R) - Thu Jan 23, 9:46AM CST
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on October 16th, 2013 at $15.92. In approximately 3 months, Momenta Pharmaceuticals has returned 20.85% as of today's recent price of $19.24.
Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee
PR Newswire - Thu Jan 23, 7:00AM CST
Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions.
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Jan 21, 3:05PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2013 before the U.S. financial markets open on Monday, February 10, 2014.
22.5% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Thu Jan 16, 9:12AM CST
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on October 16th, 2013 at $15.92. In approximately 3 months, Momenta Pharmaceuticals has returned 22.49% as of today's recent price of $19.50.
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
Commercialization Agreements, Acquisition Updates, Conference Calls Schedules, Stock Price Updates and Clinical Study Data - Research Report on Biogen Idec, Covidien, Vertex, Endo, and Momenta Pharma
PR Newswire - Tue Dec 31, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Covidien plc (NYSE: COV), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Endo Health Solutions Inc. (NASDAQ: ENDP), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
9 Top Stocks to Buy in 2014
Motley Fool Staff - Motley Fool - Sat Dec 21, 7:20AM CST
As a new year approaches, we decided to ask some of our top analysts for their favorite stock idea for 2014. Here are nine companies that look compelling right now. Jim Gillies : It's hard to find a positive word about IBM (NYSE: IBM)...
3 Quick Conclusions on a Dropped Biosimilar at Momenta Pharmaceuticals
Maxx Chatsko, The Motley Fool - Motley Fool - Fri Dec 20, 3:42PM CST
On December 19, Baxter International notified Momenta Pharmaceuticals that it was no longer interested in developing M511, a monoclonal antibody biosimilar for cancer, under a collaboration formed two years ago. The partnership sought to...
Strategic Acquisitions, Commercial Collaborations, and New Appointments - Research Report on Solta Medical, Opko Health, NuPathe, AcelRx Pharmaceuticals, and Momenta Pharmaceuticals
PR Newswire - Thu Dec 19, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Solta Medical, Inc. (NASDAQ: SLTM), Opko Health, Inc. (NYSE: OPK), NuPathe, Inc. (NASDAQ: PATH), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AnaptysBio Announces Antibody Development Agreement With Momenta
PR Newswire - Tue Dec 17, 7:00AM CST
AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the initiation of an antibody development program with Momenta Pharmaceuticals, Inc. focused on the development of novel antibodies against a therapeutically relevant target.
(0)
(0)Momenta Pharmaceuticals (MNTA) Stock Research Links
Scroll down for more posts ▼